LYTAC-mediated Degradation of Key Proteins in Hepatocellular Carcinoma and its Potential Clinical Application

Authors

  • Xumeng Ding

DOI:

https://doi.org/10.54097/5ayj1g60

Keywords:

Clinical Application, LYTAC, Key Proteins, Hepatocellular Carcinoma, HPA1, EGFR

Abstract

Lysosome-Targeting Chimeras (LYTAC) technology, with its unique mechanisms and advantages, can efficiently and specifically degrade intracellular, extracellular, and membrane proteins, offering a novel approach for hepatocellular carcinoma (HCC) treatment. This article reviews LYTAC-mediated degradation strategies targeting key proteins in HCC and their potential clinical applications. LYTAC technology employs targeting ligands to bind critical HCC proteins and directs them to lysosomes for degradation. Research has shown that this technology can effectively degrade key proteins such as heparanase (HPA1) and the epidermal growth factor receptor (EGFR), thereby inhibiting tumor cell proliferation, invasion, and metastasis while enhancing immune cell recognition and cytotoxicity against tumors. Furthermore, LYTAC technology can be combined with immunotherapy, chemotherapy, and other treatments to improve drug targeting, modulate the tumor microenvironment, and facilitate personalized medicine approaches.

Downloads

Download data is not yet available.

References

[1] Su, Q. , Wang, J. J. , Ren, J. Y. , Wu, Q. , Chen, K. , & Tu, K. H. , et al. (2024). Parkin deficiency promotes liver cancer metastasis by tmeff1 transcription activation via tgf-β/smad2/3 pathway. Acta Pharmacologica Sinica, 45(7), 1520-1529.

[2] Zhou, X. , Wu, D. , & Zhu, H. L. W. (2024). Withaferin a inhibits liver cancer tumorigenesis by suppressing aerobic glycolysis through the p53/idh1/hif-1α signaling axis. Current cancer drug targets, 24(5), 534-545.

[3] Zhang, X, Shuang, L. I. , Song, M. , Chen, Y. , Chang, L. , & Liu, Z. , et al. (2024). Degradation of fak-targeting by proteolytic targeting chimera technology to inhibit the metastasis of hepatocellular carcinoma. Oncology Research, 32(4), 679-690.

[4] Daniel Caballero-Díaz, Bertran, E., Peuelas-Haro, I. , Joaquim Moreno-Càceres, & Fabregat, I. (2020). Clathrin switches transforming growth factor-β role to pro-tumorigenic in liver cancer. Journal of Hepatology, 72(1), 125-134.

[5] Liu, F. , Yang, W. , Hu, M. , Zhang, Y. , Sun, B. , & Yang, H. , et al. (2021). Constitutive activity of gpr26 regulated by ubiquitin-dependent degradation and its antitumor role. The FEBS journal, 288(15), 4655-4682.

[6] Wang, C. , Chen, Z. , & Yi, YunDing, YangXu, FeiKang, HuiLin, KunShu, XiawenZhong, ZibiaoZhang, ZhonglinLiu, JingXu, ZhongLiu, LanHe, XingxingChang, YingZhao, Qiu. (2024). Rbm45 reprograms lipid metabolism promoting hepatocellular carcinoma via rictor and acsl1/acsl4. Oncogene, 43(5), 328-340.

[7] Ma, G. , Chen, J. , Wei, T. , Wang, J. , & Chen, W. (2021). Inhibiting roles of foxa2 in liver cancer cell migration and invasion by transcriptionally suppressing microrna-103a-3p and activating the grem2/lats2/yap axis. Cytotechnology, 73(4), 523-537.

[8] Xiao, Z. , Fan, Z. , Yawei, Z. , Jing, Z. , Jianati, D. , & Yue, P. , et al. (2018). Self-assembled dual fluorescence nanoparticles for cd44-targeted delivery of anti-mir-27a in liver cancer theranostics. Theranostics, 8(14), 3808-3823.

Downloads

Published

26-02-2025

Issue

Section

Articles

How to Cite

Ding, X. (2025). LYTAC-mediated Degradation of Key Proteins in Hepatocellular Carcinoma and its Potential Clinical Application. International Journal of Biology and Life Sciences, 9(2), 57-61. https://doi.org/10.54097/5ayj1g60